Several cancer tumours grow through immunosuppression; that is, they manipulate biological systems in their microenvironments and signal to a specific set of immune cells - those that clear out aberrant cells - to stop acting.
It is no wonder that immunotherapy designed to re-establish anti-tumour immunity is rapidly becoming the treatment of choice for these cancers.
One natural immunosuppressive molecule that falls prey to helping cancer tumours is indoleamine-2,3-dioxygenase 1 (henceforth, IDO1).
Because it is found in a broad range of cancer tumours, including those of the skin, breast, colon, lung, and blood, scientists have begun to see it as a promising therapeutic target: Suppress its activity and anti-tumour immunity should be back.
But all endeavours so far have failed in phase 3 clinical trials - the stage at which a large number of people with the disease try out the optimal dose to test its true efficacy.
Why is something so promising in theory and in the lab fizzling out in late phase clinical trials?
To find out, a team of researchers, led by Dr. Ming-Rong Zhang, Director of the Department of Advanced Nuclear Medicine Sciences at the National Institutes for Quantum and Radiological Science and Technology, Japan, tried positron emission tomography (PET) imaging to track IDO1 activity after a possible treatment has been administered.
What they found is a breakthrough now published in BMJ's Journal for ImmunoTherapy of Cancer.
"In our paper, we highlight the development cycle of our PET imaging method, starting from tracer synthesis and biomarker identification to biomarker validation in a mouse model of melanoma treated with different immunotherapy regimens," says Dr. Zhang.
The team of scientists began with a radiotracer - chemicals that emit radiation which can then be detected by machines - that is known to bind to IDO1.
After establishing that this radiotracer can reliably reflect levels of IDO1 expression at specific sites in the body, they proceeded to find out whether it can also reflect the varied treatment outcomes of three combinatory immunotherapy strategies, each involving an IDO1 inhibitor.
They administered the radiotracer and the therapies to mice with a cancerous tumour and watched what happened over time through whole-body PET imaging.
To their surprise, despite one of the treatment strategies clearly having greater efficacy than the others - wherein, IDO1 was inhibited much more than in the others - the radiotracer uptake in the tumours seemed to be the same across all treatments.
However, in the case of this standout treatment strategy, the radiotracer signal beamed in an off-tumour organ called the mesenteric lymph node.
This was not the case for the other two treatment strategies.
Further probing confirmed that in these lymph nodes as well, the radiotracer bound to IDO1.
But why this organ? That is research for another study.
In this study, the scientists went on to explore one more checkpoint: did the peak and trough of this radiotracer in the lymph nodes mirror those of maximum tumour inhibition and decline of treatment effect?
Turns out the radiotracer uptake increased from a few days before the peak, peaked with peak treatment efficacy, plateaued until a few days before treatment decline began, and fizzled out when the tumour relapsed.
So, the scientists had stumbled upon an unprecedented new biomarker with which IDO1 activity could be monitored non-invasively, a really promising alternative to the invasive biopsy.
Further explaining the results of the study, Dr. Lin Xie, co-author of the paper says, "Our findings imply that the IDO1 status in the mesenteric lymph node is an unprecedented surrogate marker of the cancer-immune set point, which is an equilibrium state from tumour tolerance to elimination, in response to immunotherapeutic intervention."
Dr. Kuan Hu, another researcher involved in the study, says, "Our study holds great potential as a robust method for visualising personalised antitumour responses in patients, to address the possible causes for the failure of the existing clinical trials, thereby improving the therapeutic outcome of IDO1 regimens. Our research also illustrates a potential precision medicine paradigm for noninvasive visualisation of each patient's individual response in combinatorial cancer immunotherapy and opens up new avenues for future clinical trials for precision anti-cancer immunotherapies."
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.